Clinical trials: Germ Cell Tumors
GCT, Germ Cell Tumor
Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
This trial is a prospective single arm intervention study, conducting clinical research on marketed drugs. Adverse drug reactions are controllable and the risk is low, with an estimated total of 40 cases.
- Conditions
- GCT, Germ Cell Tumor, Central Malignant Germ Cell Tumor
- Trial name
- NCT07188441
- Testing
- Teniposide Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chengcheng Guo
Ependymoma
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in…
- Trial name
- NCT01247922
- Testing
- Erlotinib
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 4 people
- Sponsor
- OSI Pharmaceuticals
Neuroblastoma
Nurse Case Manager Model on Neuroblastoma Caregiver's Uncertainty
Clinical Problem and Significance: The incidence of neuroblastoma is about 30 cases a year in Taiwan. The five-year survival rate of neuroblastom is near 50% in Taiwan.
- Trial name
- NCMM (NCT01525251)
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Good Prognosis Metastatic Gestational Trophoblastic Tumor, Hydatidiform Mole
Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia
Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia.
- Conditions
- Good Prognosis Metastatic Gestational Trophoblastic Tumor, Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Uterine Corpus Choriocarcinoma
- Trial name
- NCT00003702
- Testing
- Dactinomycin, Methotrexate
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Gynecologic Oncology Group
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00006246
- Testing
- busulfan
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Retinoblastoma
Efficacy Study of Lucentis in the Treatment of Retinoblastoma
This study will evaluate the clinical efficacy of intravitreal injections of Ranibizumab (Lucentis) together with chemotherapy in the treatment of Retinoblastoma as compared to chemotherapy alone.
- Trial name
- NCT01899066
- Testing
- Lucentis, chemotherapy, chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Brain Tumors
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
This study is for patients up to 21 years of age who have a tumor called a low grade glioma of the central nervous system (brain and spinal cord). The tumor has grown despite attempts to control it with chemotherapy or radiation.
- Trial name
- Poly-ICLC (NCT01188096)
- Testing
- Poly ICLC
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Neuroblastoma
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
MAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma.
- Trial name
- MAGNETO (NCT05990751)
- Testing
- GD2 CAR T cells
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College, London
Neuroblastoma, CNS Metastases
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to…
- Conditions
- Neuroblastoma, CNS Metastases, Leptomeningeal Metastases
- Trial name
- NCT03275402
- Testing
- 131I-omburtamab
- Where
- 8 sites in United States, Denmark and 2 more
- Volunteers
- 52 people
- Sponsor
- Y-mAbs Therapeutics
Head and Neck Paraganglioma
Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in Turkey
The aim of the study is to examine the head and neck paraganglioma cases treated in Pamukkale University hospital between 2007-2023 and improve our understanding of these cases and contribute to the knowledge surrounding head and…
- Trial name
- NCT05942482
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Pamukkale University
Xeroderma Pigmentosum, Basal Cell Carcinoma
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal…
- Conditions
- Xeroderma Pigmentosum, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT00046189
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Volunteers, Recurrent Glioma
MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors
This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-[F-18]fluoro-2-methyl-2-(methylamino)propanoic acid ([F-18]MeFAMP), for positron emission…
- Conditions
- Healthy Volunteers, Recurrent Glioma, Brain Metastases From Extra-cranial Solid Tumors
- Trial name
- NCT05676489
- Testing
- [F-18]MeFAMP PET
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV
International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
The HIT-HGG-2013 trial offers an innovative high-quality diagnostics and science program for children and adolescents >3 years, suffering from one of the following types of high grade gliomas: 1.
- Conditions
- Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma
- Trial name
- HIT-HGG-2013 (NCT03243461)
- Testing
- Temozolomide + Valproic Acid
- Where
- 51 sites in Germany
- Volunteers
- 167 people
- Sponsor
- University of Göttingen
Neoplasms
Continued Treatment for Participants Enrolled in Studies of BXQ-350
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the…
- Trial name
- ETERNITI (NCT04404569)
- Testing
- BXQ-350
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Brain Stem Neoplasms, Glioma
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Background: IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer growth.
- Conditions
- Brain Stem Neoplasms, Glioma, Pinealoma
- Trial name
- NCT01182883
- Testing
- IMC-A12, Temsirolimus
- Sponsor
- National Cancer Institute (NCI)
Hydatidiform Mole
A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole
Hydatidiform mole is a common complication of pregnancy with an incidence of 1in 400 pregnancies in India. Although this is a benign condition , it is having the malignant potential too.
- Trial name
- NCT01630954
- Testing
- Suction and evacuation
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Nilratan Sircar Medical College
Glioma
Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents
The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents
- Trial name
- NCT00147160
- Testing
- Temozolomide, Cisplatinum
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 87 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Newly Diagnosed High-Grade Gliomas, Diffuse Intrinsic Pontine Glioma
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
The outcome for children with high-grade gliomas and diffuse intrinsic brainstem gliomas remains poor despite the use of multi-modal therapy with surgery, radiation therapy and chemotherapy.
- Trial name
- NCT00890786
- Testing
- Temozolomide, Bevacizumab, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05885386
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Vestibular Schwannoma, Glioma, Astrocytic
USPIO Enhanced MR Imaging in CNS Tumours (UMIC)
The immune response or inflammation is known to be a key driver of progression and growth in many solid tumours. Inflammatory cells called macrophages are present in high numbers in many brain tumours and these tumour associated…
- Trial name
- UMIC (NCT06572475)
- Testing
- USPIO enhanced MRI
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Northern Care Alliance NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.